liver. Figure 4 Timeline figure indicating the procedures and chemotherapy (cetuximab) in relation to total bilirubin. Table 1 Comparison of Treated Patients and Their Characteristics and Outcomes The successful
Search Results
Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa
Wendy J. Bottinor, Yael Flamand, Naomi B. Haas, Anne M. ONeill, Robert S. DiPaola, Pearl Subramanian, David Cella, W. Gregory Hundley, Lynne I. Wagner, John M. Salsman, and Bonnie Ky
% confidence intervals were reported for all estimates. SAS 9.0 (SAS Institute Inc.) was used for all analyses. Results Patient Characteristics E2805 accrued 1,943 participants aged ≥18 years from April 2006 through September 2010. A total of 1
Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek
characteristics are provided in Table 1 . Median patient age was 62 years (range, 25–97 years), and 466 patients were female (56%) and 369 were male (44%). Of this cohort, 370 (44%) were black, 305 (37%) were white, 84 (10%) were Hispanic, 22 (3%) were Asian, 10
George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale
accredited by the American College of Surgeons Commission on Cancer in 2005; an additional 8 facilities [30%] were in the process of applying for accreditation). 21 Characteristics of the 27 facilities using CCQMS reports are detailed in Table 3
Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover
validation cohorts. Model performance of the final bootstrapped model was assessed in the training and validation cohorts using receiver operating characteristic (ROC) curves with area under the curve (AUC) statistics; ROC curves compare sensitivity to
Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall
subclassification ( P <.001). This was a generally healthy cohort, with a CDCI score of 0 in 88% of men, indicating no comorbid conditions recorded ( P =.415). Table 2. Baseline Patient Characteristics Baseline tumor characteristics across cT2 subclassifications
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo
of the Declaration of Helsinki. Use of the VHA database was approved by the St. Louis Veterans Affairs Medical Center IRB. Results Cohort Descriptions Baseline patient characteristics for the derivation (SEER-Medicare) and external validation (VHA
Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh
noncardia primaries. Demographic and clinical characteristics stratified by type of preoperative treatment are summarized in Table 1 . Among patients treated with preoperative chemotherapy, 43.8% of patients received adjuvant therapy (among whom 67
Chetna Malhotra, Ling En Koh, Irene Teo, Semra Ozdemir, Isha Chaudhry, and Eric Finkelstein
% answered surveys at 6, 12, 18, and 24 months, respectively. The 134 patients excluded from the analysis were similar to those in our analytic sample (n=466) in terms of age and sex. Table 1 shows patient baseline characteristics. Table 1. Patient
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
distribution of stage, year of diagnosis, and risk category in the treatment groups. Table 1. Patient Characteristics Some deviation from protocol-defined treatment was noted in the treatment groups ( supplemental eTable 1 ). In the chemo-PRT group, 3D
